Zimmer Biomet Holdings, Inc. (ZBH): Price and Financial Metrics

Zimmer Biomet Holdings, Inc. (ZBH)

Today's Latest Price: $142.71 USD

0.34 (-0.24%)

Updated Oct 23 7:00pm

Add ZBH to Watchlist
Sign Up

Overall POWR Rating

POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank

Industry Rank:

Ranked of 142 in Medical - Devices & Equipment

See all "A" rated Strong Buy stocks

ZBH Stock Summary

  • ZBH has a higher market value than 93.2% of US stocks; more precisely, its current market capitalization is $29,363,806,607.
  • ZBH's one year PEG ratio, measuring expected growth in earnings next year relative to current common stock price is 1,606.66 -- higher than 97.75% of US-listed equities with positive expected earnings growth.
  • ZBH's current price/earnings ratio is 800.1, which is higher than 98.96% of US stocks with positive earnings.
  • Stocks that are quantitatively similar to ZBH, based on their financial statements, market capitalization, and price volatility, are WLTW, PPG, AIG, LUV, and XYL.
  • ZBH's SEC filings can be seen here. And to visit Zimmer Biomet Holdings Inc's official web site, go to www.zimmerbiomet.com.

ZBH Stock Price Chart Interactive Chart >

Price chart for ZBH

ZBH Price/Volume Stats

Current price $142.71 52-week high $161.11
Prev. close $143.05 52-week low $74.37
Day low $142.30 Volume 723,337
Day high $144.37 Avg. volume 1,432,365
50-day MA $140.22 Dividend yield 0.67%
200-day MA $130.05 Market Cap 29.55B

Zimmer Biomet Holdings, Inc. (ZBH) Company Bio

Zimmer Biomet Holdings designs, develops, manufactures, and markets orthopaedic reconstructive devices, spinal and trauma devices, biologics, dental implants, and related surgical products in the Americas, Europe, and the Asia Pacific. The company was founded in 1927 and is based in Warsaw, Indiana.

ZBH Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$142.71$28.62 -80%

The table below illustrates the output of a discounted cash flow forecast using a variety of scenarios for Zimmer Biomet Holdings Inc. To summarize, we found that Zimmer Biomet Holdings Inc ranked in the 17th percentile in terms of potential gain offered. We should note, though, that all scenearios modelled for this stock suggest it is overvalued. As for the metrics that stood out in our discounted cash flow analysis of Zimmer Biomet Holdings Inc, consider:

  • Zimmer Biomet Holdings Inc's effective tax rate, as measured by taxes paid relative to net income, is at 89 -- greater than 96.8% of US stocks with positive free cash flow.
  • Zimmer Biomet Holdings Inc's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at -0.17. This coverage rate is greater than that of just 24.79% of stocks we're observing for the purpose of forecasting via discounted cash flows.
  • The weighted average cost of capital for the company is 11. This value is greater than 82.92% stocks in the Healthcare sector that generate free cash flow.

Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price

For other companies in the Healthcare that have a similar discounted cashflow valuation profile (and ensuing price forecasts) as ZBH, try EHC, ICUI, BHC, DHR, and TFX.

ZBH Latest News Stream

Event/Time News Detail
Loading, please wait...

ZBH Latest Social Stream

Loading social stream, please wait...

View Full ZBH Social Stream

Latest ZBH News From Around the Web

Below are the latest news stories about Zimmer Biomet Holdings Inc that investors may wish to consider to help them evaluate ZBH as an investment opportunity.

Global Leigh Syndrome Treatment Market 2020: Growth, Emerging Trends And Forecast By GlaxoSmithKline Plc, Brother Enterprises, Huazhong, Zhejiang Tianxin, Stryker Corporation, Zimmer Biomet Holdings, Inc

A new research study from “Data Bridge Market Research” with title Leigh Syndrome Treatment Insights 2020GlaxoSmithKline Plc, Brother Enterprises, Huazhong, Zhejiang Tianxin, Stryker Corporation, Zimmer Biomet Holdings, Inc., Wright Medical Technology, Inc., Integra LifeSciences Holdings Corporation among other domestic

OpenPR | October 1, 2020

Zimmer Biomet Announces Quarterly Dividend for Third Quarter of 2020

WARSAW, Ind., Sept. 10, 2020 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global leader in musculoskeletal healthcare, today announced that its Board of Directors has approved the payment of a quarterly cash dividend to stockholders for the third quarter of 2020….

PR Newswire | September 10, 2020

Needham's medtech look sees continued gains through year-end, names picks

All evidence indicates the medical technology sector hit its trough in April, as each month since has brought sequential improvement - from a springtime hole where elective medical procedures faced widespread suspensions. That meant growth slowed sharply in Q2 (-25.4% vs. Q1's -9.7%), and Needham expects declines to ease in...

Seeking Alpha | August 31, 2020

'Fast Money Halftime Report' Picks For August 13: Ollie;s, Zimmer Biomet And More

On CNBC's "Fast Money Halftime Report," Jenny Harrington suggested that Zimmer Biomet Holdings Inc (NYSE: ZBH ) is a buy. She said it has a high … Full story available on Benzinga.com

Benzinga | August 13, 2020

Will Zimmer (ZBH) Beat Estimates Again in Its Next Earnings Report?

Zimmer (ZBH) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

Yahoo | July 31, 2020

Read More 'ZBH' Stories Here

ZBH Price Returns

1-mo 5.87%
3-mo 6.50%
6-mo 24.86%
1-year 7.29%
3-year 20.84%
5-year 56.19%
YTD -4.05%
2019 45.37%
2018 -13.30%
2017 17.86%
2016 1.46%
2015 -8.80%

ZBH Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full ZBH Dividend History

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 0.762 seconds.